We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

150 Million Rapid COVID-19 Tests from Abbott Begin Rolling out Across US

By LabMedica International staff writers
Posted on 30 Sep 2020
Print article
Image: BinaxNOW COVID-19 Ag Card rapid test (Photo courtesy of Abbott)
Image: BinaxNOW COVID-19 Ag Card rapid test (Photo courtesy of Abbott)
The US government has begun distribution of 150 million COVID-19 rapid point-of-care tests from Abbott (Lake Forest, IL, USA), doubling the number of tests that have already been performed across the nation.

In an update on the national coronavirus testing strategy, President Trump stated that the US had so far conducted 111 million COVID-19 tests, far more than any other country, more than the entire European Union and more than all of Latin America combined. President Trump also announced a plan to distribute 150 million Abbott rapid point-of-care tests in the coming weeks. Abbott had recently entered into a deal worth USD 750 million with the US government to supply 150 million BinaxNOW COVID-19 Ag Card rapid tests for the detection of COVID-19 infection.

BinaxNOW is highly portable (about the size of a credit card), affordable at USD 5 and provides results in 15 minutes. The test uses proven Abbott lateral flow technology, making it a reliable and familiar format for frequent mass testing through their healthcare provider. It is intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. With no equipment required, the device will be an important tool to manage risk by quickly identifying infectious people who are currently infected and who should isolate themselves to help prevent the spread of the disease.

President Trump revealed that out of the 150 million COVID-19 rapid POC tests from Abbott to be distributed across the US in the coming weeks, 50 million tests would be allocated to protect the most vulnerable communities, including 18 million tests for nursing homes; 15 million tests for assisted living facilities; 10 million tests for home, health, and hospice care agencies; and nearly one million tests for historically black colleges and universities, and also tribal nation colleges. Additionally, the US government plans to give 100 million COVID-19 rapid POC tests from Abbott to states and territories to support efforts to reopen their economies and schools immediately and fast as they can.

“These new Abbott rapid point-of-care tests are easy to use and return results within just minutes. You’ll have a result at a maximum 15 minutes. Machine — no machine is required to process them,” said President Trump. “So, in the old days, when we just started this, you remember we’d go out and we’d have to find these massive laboratories with tremendously expensive equipment. Now we’re down to something that you’ll see that is really from a different planet.”




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more